Fibroblast growth factor receptor 3 (FGFR3) alterations in PROOF 302: A phase III trial of infigratinib (BGJ398) as adjuvant therapy in patients (pts) with invasive urothelial carcinoma (UC).

Bibliographic Details
Title:	Fibroblast growth factor receptor 3 (FGFR3) alterations in PROOF 302: A phase III trial of infigratinib (BGJ398) as adjuvant therapy in patients (pts) with invasive urothelial carcinoma (UC).
Authors:	Grivas, Petros, Daneshmand, Siamak, Makarov, Vladimir, Bellmunt, Joaquim, Sridhar, Srikala S., Sonpavde, Guru P., Cole, Suzanne, Tripathi, Abhishek, Faltas, Bishoy Morris, Lerner, Seth P., Fleming, Mark T., Loriot, Yohann, Meeks, Joshua J, Master, Viraj A., Davis, Kimberlee, Van Veenhuyzen, David Friedrich, Afifi, Shugufa, Pal, Sumanta Kumar, Gupta, Shilpa
Source:	Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p4511-4511, 1p
Database:	Supplemental Index

More Details
ISSN:	0732183X
DOI:	10.1200/JCO.2023.41.16_suppl.4511
Published in:	Journal of Clinical Oncology
Language:	English